Status: Not yet recruiting
A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
This is a randomized, open-label, multicenter Phase III clinical study designed to evaluate the efficacy and safety of SYS6043 versus investigator's choice chemotherapy in participants with platinum-resistant ovarian cancer, primary peritoneal, or fallopian tube cancer.
Participants needed: 460
Trial details
Phase: Phase 3Age: 18+Biological sex: FemaleType: InterventionalSponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.Updated: Jul 16, 2026
Eligibility criteria
Female participants aged ≥ 18 years (as of the date of signed informed consent). [+8]
Patients with platinum-refractory disease (progression within 1 month after the... [+26]